Navigation Links
PharmAthene Presents Data for SparVax(TM), a Novel Vaccine for the Prevention and Treatment of Anthrax Infection, at the 12th Annual Conference on Vaccine Research
Date:4/28/2009

, 2009. The dial-in number for U.S. callers is 1-888-286-8010, and for international callers is 617-801-6888. The participant passcode is 53903666.

The webcast of the conference call can be accessed from the company's website at http://www.pharmathene.com. A link to the webcast may be found on the Investor Relations section of the website.

About SparVax(TM)

SparVax(TM) is a novel second generation recombinant protective (rPA) anthrax vaccine being developed for pre and post exposure protection against anthrax infection. SparVax(TM) is a highly purified, well characterized, sub unit vaccine comprised of a single protein (recombinant PA) manufactured in E.coli. Phase I and Phase II clinical trials involving 770 healthy human subjects have been completed and showed that SparVax(TM) appears to be well tolerated and immunogenic in humans. These studies suggest that three doses of SparVax(TM), administered several weeks apart, should be sufficient to induce protective immunity. In preclinical studies SparVax(TM) has also demonstrated the capability to protect rabbits and non-human primates against a lethal aerosol spore challenge of the anthrax Ames strain.

About Anthrax

According to the Centers for Disease Control and Prevention, anthrax is an acute infectious disease caused by the spore-forming bacterium Bacillus anthracis. Anthrax most commonly occurs in hoofed mammals and can also infect humans. Symptoms of disease vary depending on how the disease is contracted, but usually occur within seven days after exposure. The serious forms of human anthrax are inhalation anthrax, cutaneous anthrax, and intestinal anthrax. Initial symptoms of inhalation anthrax infection may resemble a common cold. After several days, the symptoms may progress to severe breathing
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. PharmAthene Announces $5.5 Million Public Equity Offering
2. PharmAthene To Host Year-End 2008 Earnings Conference Call and Webcast on Monday, March 30, 2009
3. PharmAthene Presents Data for SparVax(TM) and Valortim(R), a Novel Vaccine and Anti-Toxin for the Prevention and Treatment of Anthrax Infection at the 7th Annual ASM Biodefense Meeting
4. PharmAthene Signs Agreement with Medison Pharma Ltd. to Commercialize and Distribute Biodefense Medical Countermeasures in Israel
5. Pharmathene Reports Third Quarter 2008 Financial and Operational Results
6. PharmAthene to Host Third Quarter 2008 Conference Call and Webcast on Thursday, November 13, 2008
7. PharmAthene to Present on Wednesday, November 12th at the 10th Annual Rodman & Renshaw Healthcare Conference
8. Medarex And PharmAthene Announce New Therapeutic Data for Anthrax Anti-Toxin, Valortim(R)
9. PharmAthene and Panacea Biotec Ltd. Establish Strategic Alliance in Biodefense and Emerging Infectious Diseases
10. PharmAthene Awarded NIAID Contract For Up to $83.9 Million For Third Generation rPA Anthrax Vaccine Program
11. PharmAthene to Present Data for Protexia(R) and Valortim(R) at HHS PHEMCE Stakeholders Workshop 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... October 31, 2014 Stronger investment ... construction, finance and consumer electronics will help fuel ... industry research firm IBISWorld has added a report ... growing industry report collection. , The Biometrics Scan ... biometric technologies such as fingerprint, iris, retina and ...
(Date:10/31/2014)... 31, 2014  Atlanta-based Intellimedix could make a ... onset of Ebola by suggesting a new, computational ... Tech,s Center for Computational Systems Biology have spent ... alternative uses for existing drugs through systematic repurposing, ... the bout against Ebola. Logo ...
(Date:10/30/2014)... LONDON , October 30, 2014 ... Organovo Holdings Inc. (NYSE MKT: ONVO), Medivation Inc. (NASDAQ: ... PCYC ), Synthetic Biologics Inc. (NYSE MKT: SYN), and ... five companies can be accessed at: http://investor-edge.com/register ... Composite ended at 4,549.23, down 0.33%, the Dow Jones ...
(Date:10/30/2014)... Global polyvinyl chloride (PVC) demand registered ... during 2008-2009, especially in North America and Europe. However, ... keeping to a growing trend. , The largest chunk ... the construction segment. In 2013, the key PVC application ... and rigid film. Moreover, the PVC was consumed in ...
Breaking Biology Technology:Biometrics Scan Software in the US Industry Market Research Report Now Available from IBISWorld 2Biometrics Scan Software in the US Industry Market Research Report Now Available from IBISWorld 3Atlanta-Based Intellimedix May Help Solve Ebola With Computer Algorithms 2Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 2Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 3Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 4Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 5Global Polyvinyl Chloride Demand Is on Upward Trend Now, Says Merchant Research & Consulting in Its Topical Study 2Global Polyvinyl Chloride Demand Is on Upward Trend Now, Says Merchant Research & Consulting in Its Topical Study 3
... a GPS-enabled asthma inhaler that will help a cutting edge epidemiology ... ... Lodge, MT (PRWEB) April 22, 2009 -- SiliconSky GPS , ... that is has successfully completed the design, development and beta-manufacturing of ...
... April 21 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: ... multiple sclerosis (MS), today announced that the independent ... pivotal phase III MAESTRO-01 Canadian/European trial of dirucotide ... a safety analysis and recommended that the trial ...
... Safety and Tumor Response Data from Dose-Escalation Study ... 100th Annual Meeting 2009 -SOUTH SAN FRANCISCO, Calif. ... (Nasdaq: PARD ), a biopharmaceutical company ... final data from a Phase 1 dose-escalation study ...
Cached Biology Technology:SiliconSky GPS Designs First AGPS-Enabled Asthma Inhaler for Landmark Research Program 2SiliconSky GPS Designs First AGPS-Enabled Asthma Inhaler for Landmark Research Program 3BioMS Medical's pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board 2Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Picoplatin in Patients with Metastatic Colorectal Cancer 2Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Picoplatin in Patients with Metastatic Colorectal Cancer 3Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Picoplatin in Patients with Metastatic Colorectal Cancer 4Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Picoplatin in Patients with Metastatic Colorectal Cancer 5
(Date:10/31/2014)... letting the air out of a nagging mystery about the ... speculated as to why animal species didn,t flourish sooner, once ... at the end of the Proterozoic period, about 800 million ... that, when most researchers think there also was plenty of ... then, after all. , In a study published Oct. 30 ...
(Date:10/31/2014)... is good for attracting species, but it may not be ... Iowa study has found. , The researchers surveyed two types ... the abundance of two insects that interact with them. They ... cherry and black walnut, they didn,t find a corresponding abundance ... on the walnuts and black cherries and a type of ...
(Date:10/31/2014)... programmed cell death, offering new targets for the treatment ... , The research teams from the Walter and Eliza ... of a key cell death protein called Bak and ... death. Their studies were published in Molecular ... National Academy of Sciences . , Programmed ...
Breaking Biology News(10 mins):Lack of oxygen delayed the rise of animals on Earth 2Green spaces don't ensure biodiversity in urban areas 2A matter of life and death: Cell death proteins key to fighting disease 2
... objects is one of the ultimate challenges in neuroscience. ... of Technology, launched an initiative with the hopes of shedding ... of his "Project Prakash" is to find, treat, and study ... that resulted from this project appears in the December 2006 ...
... shows that more people were at risk of anthrax infection ... office than previously known. The research is published in the ... available online. On the other hand, the study shows, prompt ... against the disease. , In October of 2001, a letter ...
... struggle with the heartache of infertility. Now there is the ... mutation in a gene that causes male infertility in mice. ... that leads specifically to infertility in a mammal has been ... mutations in the DNA of infertile men. , "If you ...
Cached Biology News:Anthrax attack posed greater potential threat than thought 2Researchers find gene mutation that causes infertility in male mice 2
Request Info...
Ultra-sensitive, non-radioactive detection of Protein G. Measure Protein G levels quickly and easily....
Request Info...
TRIS-EDTA based buffer prepared from RNase-free water suitable for storage and dilution of siRNA, pH 8, store at 4 C ...
Biology Products: